Sanofi
corporate_fare Company Profile
Sanofi (NASDAQ:SNY) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 46 items for SNY at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-01, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 17 rated 8 or above. Recent SEC coverage for SNY spans 6-K.
Recent high-impact activity:
- Sanofi Pays Up to $8B to Expand Regeneron Alliance With Four Long-Acting Drugs
- Sanofi Divests 20 Mature Medicines and 3 Plants to Cheplapharm for 26.4% Equity Stake
- Sanofi's MenQuadfi Wins EU Nod for Infants, Broadening Its Meningococcal Vaccine Reach
- Sanofi's H1 2026 sales hit €22.1B, guidance raised, but a €952M amlitelimab impairment weighs on results
- Sanofi Q2 Sales Surge 17.8%, Lifts 2026 Outlook; Dupixent Tops €5B/Quarter
Financial Snapshot
Short Interest & Short Volume
4.30 days to coverFINRA reported short interest of 9,297,583 shares in SNY as of the September 15, 2026 settlement, a 12.9% increase from the prior period — about 4.3 days to cover at its recent average daily volume. On October 2, 2026, 51.7% of SNY volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
SNY files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.